Gemzar (GEM-zar, gemcitabine), the first new drug for advanced pancreatic cancer in 30 years

July 1996

Lilly is now marketing Gemzar (GEM-zar, gemcitabine), the first new drug for advanced pancreatic cancer in 30 years.

It's an alternative to the usual therapy with 5-fluorouracil.

Gemzar seems to help improve survival and reduce pain.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Diabetes Humalog (insulin lispro)
Diabetes taking chromium for diabetes
Diabetes major new study to determine if Type II diabetes can be prevented or delayed
Ophthalmology Xalatan (ZAL-a-ten, latanoprost), a unique eye drop for glaucoma
changes in the package insert for the appetite suppressant Pondimin (fenfluramine)
precaution about using Pondimin with serotonergic drugs
high doses of vitamin E for tardive dyskinesia
Dermatology Retin-A for stretch marks
The FDA just approved Viramune (nevirapine)
Zithromax (azithromycin) is now approved to prevent Mycobacterium avium complex (MAC)
three important HIV tests
new test to MONITOR HIV, Amplicor HIV-1
Gastroenterology Do OTC H2-blockers work better than antacids for heartburn
Hematology & Oncology Several significant new injectable cancer drugs are now hitting the market
Hematology & Oncology Gemzar (GEM-zar, gemcitabine), the first new drug for advanced pancreatic cancer in 30 years
Hematology & Oncology Hycamtin (Hy-CAM-tin, topotecan) for ovarian cancer
Hematology & Oncology Camptosar (irinotecan), the first new drug for colorectal cancer in 40 years